JP2015531377A5 - - Google Patents

Download PDF

Info

Publication number
JP2015531377A5
JP2015531377A5 JP2015534679A JP2015534679A JP2015531377A5 JP 2015531377 A5 JP2015531377 A5 JP 2015531377A5 JP 2015534679 A JP2015534679 A JP 2015534679A JP 2015534679 A JP2015534679 A JP 2015534679A JP 2015531377 A5 JP2015531377 A5 JP 2015531377A5
Authority
JP
Japan
Prior art keywords
vehicle
weight
liquid formulation
content
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015534679A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015531377A (ja
JP6248112B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/062051 external-priority patent/WO2014052678A1/en
Publication of JP2015531377A publication Critical patent/JP2015531377A/ja
Publication of JP2015531377A5 publication Critical patent/JP2015531377A5/ja
Application granted granted Critical
Publication of JP6248112B2 publication Critical patent/JP6248112B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015534679A 2012-09-26 2013-09-26 アピキサバン液体製剤 Expired - Fee Related JP6248112B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261705943P 2012-09-26 2012-09-26
US61/705,943 2012-09-26
US201361773032P 2013-03-05 2013-03-05
US61/773,032 2013-03-05
PCT/US2013/062051 WO2014052678A1 (en) 2012-09-26 2013-09-26 Apixaban liquid formulations

Publications (3)

Publication Number Publication Date
JP2015531377A JP2015531377A (ja) 2015-11-02
JP2015531377A5 true JP2015531377A5 (cg-RX-API-DMAC7.html) 2016-11-10
JP6248112B2 JP6248112B2 (ja) 2017-12-13

Family

ID=49447800

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015534679A Expired - Fee Related JP6248112B2 (ja) 2012-09-26 2013-09-26 アピキサバン液体製剤

Country Status (18)

Country Link
US (2) US9452134B2 (cg-RX-API-DMAC7.html)
EP (1) EP2900217A1 (cg-RX-API-DMAC7.html)
JP (1) JP6248112B2 (cg-RX-API-DMAC7.html)
KR (1) KR102035373B1 (cg-RX-API-DMAC7.html)
CN (1) CN104736142B (cg-RX-API-DMAC7.html)
AU (1) AU2013323435C1 (cg-RX-API-DMAC7.html)
BR (1) BR112015005995A2 (cg-RX-API-DMAC7.html)
CA (1) CA2885899A1 (cg-RX-API-DMAC7.html)
HK (1) HK1212900A1 (cg-RX-API-DMAC7.html)
IL (1) IL237804A0 (cg-RX-API-DMAC7.html)
IN (1) IN2015DN01902A (cg-RX-API-DMAC7.html)
MX (1) MX358097B (cg-RX-API-DMAC7.html)
MY (1) MY179191A (cg-RX-API-DMAC7.html)
NZ (1) NZ630763A (cg-RX-API-DMAC7.html)
PH (1) PH12015500590B1 (cg-RX-API-DMAC7.html)
RU (1) RU2660358C2 (cg-RX-API-DMAC7.html)
SG (2) SG10201702048VA (cg-RX-API-DMAC7.html)
WO (1) WO2014052678A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2907507A1 (en) * 2014-02-17 2015-08-19 Sandoz Ag Pharmaceutical composition comprising apixaban
WO2017221209A1 (en) 2016-06-23 2017-12-28 Lupin Limited Pharmaceutical formulations of apixaban
HUE067789T2 (hu) * 2018-04-16 2024-11-28 Bristol Myers Squibb Co Apixaban formulációk
CN112261935A (zh) 2018-08-14 2021-01-22 江苏恒瑞医药股份有限公司 一种可注射的药物组合物及其制备方法
PH12022551126A1 (en) 2019-11-13 2023-08-23 Unison Pharmaceuticals Pvt Ltd Orally disintegrating pharmaceutical compositions of apixaban
US20240041856A1 (en) * 2020-12-13 2024-02-08 Dafechem Limited Liquid apixaban formulation in small dose volume
CN113384526A (zh) * 2021-08-03 2021-09-14 合肥医工医药股份有限公司 一种稳定的阿哌沙班口服溶液制剂及其制备方法
NL2029536B1 (en) 2021-10-27 2023-05-26 Pharma Data S A Apixaban suspension and preparation method
US12214075B2 (en) 2021-10-27 2025-02-04 Pharma-Data Research And Development Single Member S.A. Apixaban suspension and preparation method
US12194028B2 (en) 2022-03-09 2025-01-14 Slayback Pharma Llc Stable pharmaceutical compositions of apixaban
WO2023218482A1 (en) * 2022-05-09 2023-11-16 Syri Research Private Limited Liquid oral formulation of apixaban or pharmaceutically acceptable salt thereof
US12213972B2 (en) * 2022-07-27 2025-02-04 Slayback Pharma Llc Stable pharmaceutical compositions of apixaban
EP4658238A1 (en) 2023-01-30 2025-12-10 TAP Pharmaceuticals AG Liquid pharmaceutical formulations of apixaban
US11833138B1 (en) 2023-01-30 2023-12-05 Tap Pharmaceuticals Ag Liquid pharmaceutical formulations of apixaban
EP4450064A1 (en) 2023-04-14 2024-10-23 Novick BioSciences Private Limited Apixaban compositions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763449A (en) * 1996-08-07 1998-06-09 Ascent Pediatrics, Inc. Pleasant-tasting aqueous liquid composition of a bitter-tasting drug
SK8562002A3 (en) 1999-12-23 2003-10-07 Pfizer Prod Inc Pharmaceutical compositions providing enhanced drug concentrations
MY129350A (en) * 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
EP1269994A3 (en) 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
TWI331526B (en) 2001-09-21 2010-10-11 Bristol Myers Squibb Pharma Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
KR100909141B1 (ko) * 2001-09-21 2009-07-23 브리스톨-마이어스스퀴브컴파니 인자 Xa 억제제로서의 락탐-함유 화합물 및 그의 유도체
US7101572B2 (en) * 2001-12-07 2006-09-05 Unilab Pharmatech, Ltd. Taste masked aqueous liquid pharmaceutical composition
JP2008531556A (ja) * 2005-02-25 2008-08-14 バイオマリン ファーマシューティカル インコーポレイテッド 室温で安定な水性の液状薬学的組成物
US20070191306A1 (en) * 2005-08-17 2007-08-16 Bristol-Myers Squibb Company FACTOR Xa INHIBITOR FORMULATION AND METHOD
CA2712120A1 (en) * 2008-01-14 2009-07-23 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
KR101991367B1 (ko) * 2009-05-13 2019-06-21 사이덱스 파마슈티칼스, 인크. 프라수그렐 및 사이클로덱스트린 유도체를 포함하는 약학 조성물 및 그의 제조 및 사용 방법
SMT202000093T1 (it) * 2009-06-16 2020-03-13 Pfizer Forme di dosaggio di apixaban
ES2757603T3 (es) * 2010-02-25 2020-04-29 Bristol Myers Squibb Holdings Ireland Formulaciones de apixabán
EP2484775A1 (de) 2011-02-07 2012-08-08 Siemens Healthcare Diagnostics Products GmbH Heparin-insensitives Verfahren zur Bestimmung von direkten Gerinnungsfaktorinhibitoren
RU2638155C1 (ru) * 2016-02-29 2017-12-12 Общество С Ограниченной Ответственностью "Сай Фарма" Производные бензо[d]изоксазола и их применение

Similar Documents

Publication Publication Date Title
JP2015531377A5 (cg-RX-API-DMAC7.html)
RU2015115127A (ru) Жидкие лекарственные композиции апиксабана
AU2021229177B2 (en) Diacerein or rhein topical formulations and uses thereof
ES2545395T3 (es) Asociación de ivermectina con brimonidina para el tratamiento o prevención de la rosácea
US9642848B2 (en) Sublingual naloxone spray
AR103653A1 (es) Complejos de acetato de abiraterona, proceso para prepararlos y composiciones farmacéuticas que los contienen
RU2016103753A (ru) Лечение воспалительных повреждений при розациа с помощью ивермектина
JP2016503030A5 (cg-RX-API-DMAC7.html)
AR073793A1 (es) Formulacion farmaceutica liquida que contiene paracetamol. excipiente liquido
WO2012083138A3 (en) Azole pharmaceutical formulations for parenteral administration and methods for preparing and using the same as treatment of diseases sensitive to azole compounds
RU2014101990A (ru) Жидкая фармацевтическая композиция, включающая нитизинон
CN113301884A (zh) 非水性化疗口服悬浮液
EP3277283B1 (en) Sildenafil sublingual spray formulations
US9370518B2 (en) Sildenafil sublingual spray formulation
RU2021102950A (ru) Твердые фармацевтические композиции для лечения вируса гепатита с
JP2015518000A5 (cg-RX-API-DMAC7.html)
US10512625B2 (en) Diacerein or rhein topical formulations and uses thereof
AR086252A1 (es) Formulacion topica que comprende dipropionato de beclometasona como ingrediente activo
EP3218060B1 (en) Sprayable analgesic compositions
US10154984B2 (en) Diacerein or Rhein topical formulations and uses thereof
JP5992293B2 (ja) 眼科用剤
US20200230082A1 (en) Topical acetaminophen formulations for itch relief
EP3481370B1 (en) Pharmaceutical composition comprising benzydamine
Kovács et al. P044-DeveloPmeNT of A PAreNTerAl SolveNT SYSTem for THe SoluBIlIZATIoN of AZole TYPe ANTIfuNgAlS
HK40004836B (en) Pharmaceutical composition comprising benzydamine